LAWRENCE, Mass., June 24, 2015 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of dialysis products, is proud to announce that today is the 10th year anniversary of the Food and Drug Administration’s (FDA) clearance of its revolutionary System One. In recognition of this milestone, the Company is celebrating the personal achievements of patients performing home hemodialysis (HHD) with the NxStage® System One. This summer-long celebration will promote the significant life changing benefits made possible with HHD, feature the System One’s market leading technology, and promote NxStage’s decade long role in helping patients regain control of their lives.
Over ten years ago, NxStage set out to innovate a dialysis treatment paradigm that could provide patients with access to more therapy options to meet both their clinical and lifestyle needs. Today, NxStage’s System One is the first and only portable dialysis machine that enables patients to perform dialysis in their homes or while traveling, during the day or at night while sleeping. It has been used to perform over ten million treatments on thousands of patients around the world, changing the way patients and clinicians think about hemodialysis.
Jenna Smith is a 29-year-old Seattle resident with a rare condition called Dense Deposit Disease (DDD) which led to her kidney failure. Smith tried a range of treatment options for kidney failure, including a failed transplant from her father and in-center hemodialysis. She chose HHD with the System One ten years ago because the in-center treatment regimen posed challenges for her individual healthcare needs due to the lack of frequency and flexibility of the therapy. While treating with the System One, Smith graduated from the University of Iowa, moved to Oregon, earned her graduate degree, and now works in 3D digital modeling at an engineering firm in Seattle.
“The number of personal goals I’ve achieved over the past 10 years would not have been possible without the NxStage System One,” said Smith. “I’m extremely thankful to have found home hemodialysis because my treatment fits into my life whenever and wherever I want, instead of the other way around.”
“A decade after launching the first System One, we continue to redefine renal care by allowing patients to take back control of their lives with home hemodialysis treatments tailored to their own needs,” said Joseph E. Turk, President of NxStage. “We’re committed to improving the lives of dialysis patients with more groundbreaking innovations in the years ahead.”
Visit our Facebook page www.facebook.com/NxStage to read more inspiring patient stories throughout the summer. If you would like to share your personal achievements while using the System One please email our patient marketing team at patientstories@nxstage.com.
For more information about the System One, home hemodialysis or home nocturnal hemodialysis, please visit www.nxstage.com.
Despite the health benefits that home hemodialysis may provide to those with chronic kidney disease, this form of therapy is not for everyone. The reported benefits of home hemodialysis may not be experienced by all patients. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream and blood loss due to clotting or accidental disconnection of the blood tubing set. Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed.
Additional Risks Associated with Nocturnal Home Hemodialysis Therapy
The NxStage System One may be used at night while the patient and care partner are sleeping. Certain risks associated with hemodialysis treatment are increased when performing nocturnal therapy due to the length of treatment time and because therapy is performed while the patient and care partner are sleeping. These risks include, but are not limited to, blood access disconnects and blood loss during sleep, blood clotting due to slower blood flow or increased treatment time or both, and delayed response to alarms when waking from sleep. Ancillary anticoagulant infusion pumps and fluid leak detection devices may be used to decrease certain risks for home hemodialysis treatments performed at any time, but NxStage requires the use of fluid leak detectors to identify leaks from the vascular access, Cycler and Cartridge when performing nocturnal therapy with the NxStage System One.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis and home nocturnal hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients’ homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. http://www.nxstage.com/.
About NxStage Medical
NxStage Medical Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company’s website at www.nxstage.com.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words “anticipate,” “believe,” “expect,” “estimate,” “plan,” and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage’s filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2015. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Media contact:
Kristen K. Sheppard, Esq.
ksheppard@nxstage.com
Tel: (978) 332-5923
Photo - http://photos.prnewswire.com/prnh/20150624/225341
Logo - http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nxstage-kicks-off-10th-anniversary-of-innovation-milestone-with-summer-long-celebration-of-patient-life-achievements-300104071.html
SOURCE NxStage Medical, Inc.
Help employers find you! Check out all the jobs and post your resume.
